Edition:
United States

Verastem Inc (VSTM.OQ)

VSTM.OQ on NASDAQ Stock Exchange Global Market

4.05USD
14 Dec 2018
Change (% chg)

$-0.08 (-1.94%)
Prev Close
$4.13
Open
$4.11
Day's High
$4.25
Day's Low
$4.01
Volume
428,078
Avg. Vol
598,885
52-wk High
$10.34
52-wk Low
$2.78

Latest Key Developments (Source: Significant Developments)

Verastem Oncology Q3 Loss Per Share $0.29
Wednesday, 7 Nov 2018 04:05pm EST 

Nov 7 (Reuters) - Verastem Inc ::VERASTEM ONCOLOGY REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.29.Q3 EARNINGS PER SHARE VIEW $-0.42 -- THOMSON REUTERS I/B/E/S.AS OF SEPTEMBER 30, 2018, VERASTEM ONCOLOGY HAD CASH, CASH EQUIVALENTS AND INVESTMENTS OF $145.6 MILLION.QTRLY TOTAL REVENUE 15.5 MILLION.  Full Article

Verastem Oncology Announces Public Offering Of 7.78 Mln Common Shares Priced At $4.50per Share
Wednesday, 16 May 2018 09:29am EDT 

May 16 (Reuters) - Verastem Inc ::VERASTEM ONCOLOGY ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 7.78 MILLION COMMON SHARES PRICED AT $4.50PER SHARE.  Full Article

FDA Accepts New Drug Application For Duvelisib And Grants Priority Review
Monday, 9 Apr 2018 03:00am EDT 

April 9 (Reuters) - Verastem Inc ::FDA ACCEPTS NEW DRUG APPLICATION FOR DUVELISIB AND GRANTS PRIORITY REVIEW.‍FDA TARGET ACTION DATE IS OCTOBER 5, 2018​.  Full Article

Verastem Reports Year-End 2017 Financial Results
Tuesday, 13 Mar 2018 07:00am EDT 

March 13 (Reuters) - Verastem Inc ::VERASTEM REPORTS YEAR-END 2017 FINANCIAL RESULTS.VERASTEM - EXPECTS TO HAVE SUFFICIENT CASH, CASH EQUIVALENTS AND INVESTMENTS TO FUND CURRENT OPERATING PLAN AND CAPEX REQUIREMENTS INTO H2 2018.  Full Article

Verastem Submits Marketing Application To FDA For Duvelisib
Wednesday, 7 Feb 2018 07:00am EST 

Feb 7 (Reuters) - Verastem Inc ::VERASTEM SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR DUVELISIB FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA AND FOLLICULAR LYMPHOMA.VERASTEM INC - LOOK FORWARD TO WORKING WITH FDA DURING REVIEW PROCESS AND TO POTENTIAL U.S. APPROVAL DECISION FOR DUVELISIB IN EARLY 2019.  Full Article

Verastem Announces Increased Hercules Debt Facility
Thursday, 4 Jan 2018 04:01pm EST 

Jan 4 (Reuters) - Verastem Inc ::VERASTEM ANNOUNCES INCREASED HERCULES DEBT FACILITY.VERASTEM INC - ANNOUNCED ENTRY INTO AN AMENDMENT TO ITS LOAN AND SECURITY AGREEMENT WITH HERCULES CAPITAL INC.VERASTEM INC - ‍INCREASING ITS EXISTING BORROWING LIMIT UNDER LOAN FACILITY FROM $25 MILLION TO UP TO $50 MILLION IN FINANCING​.VERASTEM INC - ‍VERASTEM HAS RECEIVED FIRST $15 MILLION OF FINANCING UNDER ORIGINAL LOAN AND SECURITY AGREEMENT​.VERASTEM - ‍INCREASED LOAN FACILITY PROCEEDS TO BE USED FOR DEVELOPMENT PROGRAMS, INCLUDING REGULATORY & COMMERCIALIZATION ACTIVITIES FOR DUVELISIB​.  Full Article

Verastem Announces Pricing Of Public Offering Of Common Stock
Friday, 15 Dec 2017 09:18am EST 

Verastem Inc ::VERASTEM ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.VERASTEM INC - ANNOUNCED PRICING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF APPROXIMATELY $25 MILLION OF SHARES OF ITS COMMON STOCK.  Full Article

Verastem Announces Public Offering Of Common Stock
Thursday, 14 Dec 2017 05:07pm EST 

Dec 14 (Reuters) - Verastem Inc ::VERASTEM ANNOUNCES PUBLIC OFFERING OF COMMON STOCK.VERASTEM INC - INTENDS TO OFFER AND SELL $25 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.  Full Article

‍Verastem Announces Clinical Data From Pivotal Phase 3 Duo Study​
Sunday, 10 Dec 2017 04:30pm EST 

Dec 10 (Reuters) - Verastem Inc ::‍VERASTEM ANNOUNCES CLINICAL DATA FROM PIVOTAL PHASE 3 DUO™ STUDY​.‍DUO STUDY ACHIEVES PRIMARY ENDPOINT, DEMONSTRATING STATISTICALLY SIGNIFICANT IMPROVEMENT IN PFS FOR DUVELISIB VERSUS OFATUMUMAB​.‍PLANS TO SUBMIT A NDA TO U.S. FDA REQUESTING FULL APPROVAL OF DUVELISIB​.‍PLANS TO SUBMIT ACCELERATED APPROVAL OF DUVELISIB FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY FL ​.‍EXPECTS TO SUBMIT DUVELISIB NDA DURING Q1 OF 2018​.  Full Article

Verastem reports Q3 loss per share of $0.61
Tuesday, 7 Nov 2017 07:00am EST 

Nov 7 (Reuters) - Verastem Inc :Verastem reports third quarter 2017 financial results.Q3 loss per share $0.61.Q3 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S.Verastem - based on current plans,​ ‍expect to have sufficient cash, cash equivalents & investments to fund research and development programs & operations into H2 2018.  Full Article